Alpha 2.0
Login Register
» Articles » PMID: 2386379

Nephrotoxicity After Ifosfamide

Overview
Journal Arch Dis Child
Specialty Pediatrics
Date 1990 Jul 1
PMID 2386379
Citations 32
Authors
R Skinner
A D Pearson
L Price
M G Coulthard
A W Craft
Affiliations
Soon will be listed here.
Abstract

Eleven children and adolescents with previously normal renal function who received ifosfamide for the treatment of extrarenal solid tumours underwent detailed investigation of glomerular and renal tubular function to assess the incidence and extent of renal damage. None had received cisplatin. Glomerular filtration rate (measured by plasma clearance of 51Cr labelled edetic acid) was reduced in six children. All 11 patients had evidence of proximal, and six of distal, tubular damage. Proximal tubular toxicity was indicated by phosphaturia and hypophosphataemia (n = 4), glycosuria (n = 5), increased urine beta 2 microglobulin excretion (n = 11), and generalised aminoaciduria (n = 10); distal tubular damage caused a reduction of the osmolality of the urine in an early morning sample. Two children developed clinical hypophosphataemic rickets, and one of these also had severe nephrogenic diabetes insipidus. Glomerular and tubular nephrotoxicity are common and potentially serious complications of ifosfamide treatment in children.

Citing Articles

Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.

Febvey-Combes O, Guitton J, Marec-Berard P, Faure-Conter C, Blanc E, Chabaud S BMC Pediatr. 2024; 24(1):196.

PMID: 38504218 PMC: 10949630. DOI: 10.1186/s12887-024-04633-1.

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.

Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T Int J Clin Oncol. 2023; 28(10):1259-1297.

PMID: 37382749 DOI: 10.1007/s10147-023-02372-4.

Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.

Matsubara T, Yokoi H, Yamada H, Yanagita M Int J Clin Oncol. 2023; 28(5):625-636.

PMID: 36872414 DOI: 10.1007/s10147-023-02307-z.

19-year-old Woman with Intermittent Weakness.

Cavaliere G, Murali N, Bontempo L, Dezman Z Clin Pract Cases Emerg Med. 2021; 5(3):276-282.

PMID: 34437031 PMC: 8373190. DOI: 10.5811/cpcem.2021.4.52011.

Ifosfamide-induced nephrogenic diabetes insipidus responsive to supraphysiologic doses of intravenous desmopressin.

Sohail M, Hassanein M, Rincon-Choles H Clin Nephrol Case Stud. 2021; 9:87-92.

PMID: 34235046 PMC: 8259464. DOI: 10.5414/CNCS110589.

References
1.
Knapp M, Hadid O . Investigations into negative interference by jaundiced plasma in kinetic Jaffé methods for plasma creatinine determination. Ann Clin Biochem. 1987; 24 ( Pt 1):85-97. DOI: 10.1177/000456328702400114. View
2.
Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J . A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol. 1986; 18 Suppl 2:S25-8. DOI: 10.1007/BF00647446. View
3.
Fillastre J, Viotte G, Morin J, Moulin B . Nephrotoxicity of antitumoral agents. Adv Nephrol Necker Hosp. 1988; 17:175-218. View
4.
Sawyer M, Webb D, Balow J, Straus S . Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988; 84(6):1067-71. DOI: 10.1016/0002-9343(88)90313-0. View
5.
Hadidi A, Coulter C, Idle J . Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res. 1988; 48(18):5167-71. View